Skip to main content
SpringerLink
Log in

Analysis of Conservative Treatment of Upper Tract Urothelial Carcinoma

  • Chapter
  • First Online:
Urothelial Malignancies of the Upper Urinary Tract

  • 398 Accesses

Abstract

A survey of literature on UTUC shows a mix set of results on efficacy and outcome of conservative treatment. There are no standardized templates for ureteroscopic or percutaneous resection techniques nor the adjuvant treatment options. The assumptions of what institutes a diagnosis or success after treatment also remain unclear. The conservative management of UTUC is a work in progress requiring a multicenter prospective evaluation to provide more clear parameters to follow.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution

Institutional subscriptions

References

  1. Schmeller NT, Hofstetter AG. Laser treatment of ureteral tumors. J Urol. 1989;141:840.

    Article  CAS  PubMed  Google Scholar 

  2. Gaboardi F, Bozzola A, Dotti E, et al. Conservative treatment of upper urinary tract tumors with Nd:YAG laser. J Endourol. 1994;8:37.

    Article  CAS  PubMed  Google Scholar 

  3. Martinez-Piñeiro JA, Garcia Matres MJ, Martinez-Piñeiro L. Endourological treatment of upper tract urothelial carcinomas: analysis of a series of 59 tumors. J Urol. 1996;156:377.

    Article  PubMed  Google Scholar 

  4. Roupret M, Hupertan V, Traxer O, et al. Comparison of open nephroureterectomy and ureteroscopic and percutaneous management of upper urinary tract transitional cell carcinoma. Urology. 2006;67:1181.

    Article  PubMed  Google Scholar 

  5. Lucas SM, Svatek RS, Olgin G, et al. Conservative management in selected patients with upper tract urothelial carcinoma compares favourably with early radical surgery. BJU Int. 2008;102:172.

    Article  PubMed  Google Scholar 

  6. Cutress ML, Stewart GD, Zakikhani P, et al. Ureteroscopic and percutaneous management of upper tract urothelial carcinoma (UTUC): systematic review. BJU Int. 2012;110:614.

    Article  PubMed  Google Scholar 

  7. Grasso M, Fishman AI, Cohen J, et al. Ureteroscopic and extirpative treatment of upper urinary tract urothelial carcinoma: a 15-year comprehensive review of 160 consecutive patients. BJU Int. 2012;110:1618.

    Article  PubMed  Google Scholar 

  8. Gadzinski AJ, Roberts WW, Faerber GJ, et al. Long-term outcomes of immediate versus delayed nephroureterectomy for upper tract urothelial carcinoma. J Endourol. 2012;26:566.

    Article  PubMed  Google Scholar 

  9. Raymundo EM, Lipkin ME, Bañez LB, et al. Third prize: the role of endoscopic nephron-sparing surgery in the management of upper tract urothelial carcinoma. J Endourol. 2011;25:377.

    Article  PubMed  Google Scholar 

  10. Pak RW, Moskowitz EJ, Bagley DH. What is the cost of maintaining a kidney in upper-tract transitional-cell carcinoma? An objective analysis of cost and survival. J Endourol. 2009;23:341.

    Article  PubMed  Google Scholar 

  11. Engelmyer EI, Belis JA. Long-term ureteroscopic management of low-grade transitional cell carcinoma of the upper urinary tract. Tech Urol. 1996;2:113.

    PubMed  CAS  Google Scholar 

  12. Daneshmand S, Quek ML, Huffman JL. Endoscopic management of upper urinary tract transitional cell carcinoma: long-term experience. Cancer. 2003;98:55.

    Article  PubMed  Google Scholar 

  13. Johnson GB, Fraiman M, Grasso M. Broadening experience with the retrograde endoscopic management of upper urinary tract urothelial malignancies. BJU Int. 2005;95(Suppl. 2):110.

    Article  PubMed  Google Scholar 

  14. Krambeck AE, Thompson RH, Lohse CM, et al. Endoscopic management of upper tract urothelial carcinoma in patients with a history of bladder urothelial carcinoma. J Urol. 2007;177:1721.

    Article  PubMed  Google Scholar 

  15. Cornu JN, Rouprêt M, Carpentier X, et al. Oncologic control obtained after exclusive flexible ureteroscopic management of upper urinary tract urothelial cell carcinoma. World J Urol. 2010;28:151.

    Article  PubMed  Google Scholar 

  16. Gadzinski AJ, Roberts WW, Faerber GJ, et al. Long-term outcomes of nephroureterectomy versus endoscopic management for upper tract urothelial carcinoma. J Urol. 2010;183:2148.

    Article  PubMed  Google Scholar 

  17. Cutress ML, Stewart GD, Tudor EC, et al. Endoscopic versus laparoscopic management of noninvasive upper tract urothelial carcinoma: 20-year single center experience. J Urol. 2013;189:2054.

    Article  PubMed  Google Scholar 

  18. Thompson RH, Krambeck AE, Lohse CM, et al. Endoscopic management of upper tract transitional cell carcinoma in patients with normal contralateral kidneys. Urology. 2008;71:713.

    Article  PubMed  Google Scholar 

  19. Deligne E, Colombel M, Badet L, et al. Conservative management of upper urinary tract tumors. Eur Urol. 2002;42:43.

    Article  PubMed  Google Scholar 

  20. Lee BR, Jabbour ME, Marshall FF, et al. 13-year survival comparison of percutaneous and open nephroureterectomy approaches for management of transitional cell carcinoma of renal collecting system: equivalent outcomes. J Endourol. 1999;13:289.

    Article  CAS  PubMed  Google Scholar 

  21. Fuglsig S, Krarup T. Percutaneous nephroscopic resection of renal pelvic tumors. Scand J Urol Nephrol Suppl. 1995;172:15.

    PubMed  CAS  Google Scholar 

  22. Jabbour ME, Smith AD. Primary percutaneous approach to upper urinary tract transitional cell carcinoma. Urol Clin North Am. 2000;27:739.

    Article  CAS  PubMed  Google Scholar 

  23. Irwin BH, Berger AK, Brandina R, et al. Complex percutaneous resections for upper-tract urothelial carcinoma. J Endourol. 2010;24:367.

    Article  PubMed  Google Scholar 

  24. Tasca A, Zattoni F. The case for a percutaneous approach to transitional cell carcinoma of the renal pelvis. J Urol. 1990;143:902.

    Article  CAS  PubMed  Google Scholar 

  25. Plancke HR, Strijbos WE, Delaere KP. Percutaneous endoscopic treatment of urothelial tumours of the renal pelvis. Br J Urol. 1995;75:736.

    Article  CAS  PubMed  Google Scholar 

  26. Patel A, Soonawalla P, Shepherd SF, et al. Long-term outcome after percutaneous treatment of transitional cell carcinoma of the renal pelvis. J Urol. 1996;155:868.

    Article  CAS  PubMed  Google Scholar 

  27. Martínez-Piñeiro JA, García Matres MJ, Martínez-Piñeiro L. Endourological treatment of upper tract urothelial carcinomas: analysis of a series of 59 tumors. J Urol. 1996;156:377.

    Article  PubMed  Google Scholar 

  28. Clark PE, Streem SB, Geisinger MA. 13-year experience with percutaneous management of upper tract transitional cell carcinoma. J Urol. 1999;161:772.

    Article  CAS  PubMed  Google Scholar 

  29. Goel MC, Mahendra V, Roberts JG. Percutaneous management of renal pelvic urothelial tumors: long-term followup. J Urol. 2003;169:925.

    Article  PubMed  Google Scholar 

  30. Suh RS, Faerber GJ, Wolf JS. Predictive factors for applicability and success with endoscopic treatment of upper tract urothelial carcinoma. J Urol. 2003;170:2209.

    Article  PubMed  Google Scholar 

  31. Palou J, Piovesan LF, Huguet J, et al. Percutaneous nephroscopic management of upper urinary tract transitional cell carcinoma: recurrence and long-term followup. J Urol. 2004;172:66.

    Article  PubMed  Google Scholar 

  32. Rouprêt M, Traxer O, Tligui M, et al. Upper urinary tract transitional cell carcinoma: recurrence rate after percutaneous endoscopic resection. Eur Urol. 2007;51:709.

    Article  PubMed  Google Scholar 

  33. Motamedinia P, Keheila M, Leavitt DA, et al. The expanded use of percutaneous resection for upper tract urothelial carcinoma: a 30-year comprehensive experience. J Endourol. 2015;30:262–7.

    Article  PubMed  Google Scholar 

  34. Herr HW. Durable response of a carcinoma in situ of the renal pelvis to topical bacillus Calmette-Guerin. J Urol. 1985;134:531.

    Article  CAS  PubMed  Google Scholar 

  35. Nonomura N, Ono Y, Nozawa M, et al. Bacillus Calmette-Guérin perfusion therapy for the treatment of transitional cell carcinoma in situ of the upper urinary tract. Eur Urol. 2000;38:701.

    Article  CAS  PubMed  Google Scholar 

  36. Okubo K, Ichioka K, Terada N, et al. Intrarenal bacillus Calmette-Guérin therapy for carcinoma in situ of the upper urinary tract: long-term follow-up and natural course in cases of failure. BJU Int. 2001;88:343.

    Article  CAS  PubMed  Google Scholar 

  37. Miyake H, Eto H, Hara S, et al. Clinical outcome of bacillus Calmette-Guérin perfusion therapy for carcinoma in situ of the upper urinary tract. Int J Urol. 2002;9:677.

    Article  PubMed  Google Scholar 

  38. Hayashida Y, Nomata K, Noguchi M, et al. Long-term effects of bacille Calmette-Guérin perfusion therapy for treatment of transitional cell carcinoma in situ of upper urinary tract. Urology. 2004;63:1084.

    Article  PubMed  Google Scholar 

  39. Kojima Y, Tozawa K, Kawai N, et al. Long-term outcome of upper urinary tract carcinoma in situ: effectiveness of nephroureterectomy versus bacillus Calmette-Guérin therapy. Int J Urol. 2006;13:340.

    Article  PubMed  Google Scholar 

  40. Giannarini G, Kessler TM, Birkhauser FD, et al. Antegrade perfusion with bacillus Calmette-Guerin in patients with non-muscle-invasive urothelial carcinoma of the upper urinary tract: who may benefit? Eur Urol. 2011;60:955.

    Article  PubMed  Google Scholar 

  41. Sharpe JR, Duffy G, Chin JL. Intrarenal bacillus Calmette-Guerin therapy for upper urinary tract carcinoma in situ. J Urol. 1993;149:457.

    Article  CAS  PubMed  Google Scholar 

  42. Yokogi H, Wada Y, Mizutani M, et al. Bacillus Calmette-Guérin perfusion therapy for carcinoma in situ of the upper urinary tract. Br J Urol. 1996;77:676.

    Article  CAS  PubMed  Google Scholar 

  43. Nishino Y, Yamamoto N, Komeda H, et al. Bacillus Calmette-Guérin instillation treatment for carcinoma in situ of the upper urinary tract. BJU Int. 2000;85:799.

    Article  CAS  PubMed  Google Scholar 

  44. Irie A, Iwamura M, Kadowaki K, et al. Intravesical instillation of bacille Calmette-Guérin for carcinoma in situ of the urothelium involving the upper urinary tract using vesicoureteral reflux created by a double-pigtail catheter. Urology. 2002;59:53.

    Article  PubMed  Google Scholar 

  45. Studer UE, Casanova G, Kraft R, et al. Percutaneous BCG perfusion of the upper urinary tract for carcinoma in situ. Prog Clin Biol Res. 1989;310:207.

    PubMed  CAS  Google Scholar 

  46. Schoenberg MP, Van Arsdalen KN, Wein AJ. The management of transitional cell carcinoma in solitary renal units. J Urol. 1991;146:700.

    Article  CAS  PubMed  Google Scholar 

  47. Jarrett TW, Sweetser PM, Weiss GH, et al. Percutaneous management of transitional cell carcinoma of the renal collecting system: 9-year experience. J Urol. 1995;154:1629.

    Article  CAS  PubMed  Google Scholar 

  48. Patel A, Fuchs GJ. New techniques for the administration of topical adjuvant therapy after endoscopic ablation of upper urinary tract transitional cell carcinoma. J Urol. 1998;159:71.

    Article  CAS  PubMed  Google Scholar 

  49. Rastinehad AR, Ost MC, Vanderbrink BA, et al. A 20-year experience with percutaneous resection of upper tract transitional carcinoma: is there an oncologic benefit with adjuvant bacillus Calmette Guérin therapy? Urology. 2009;73:27.

    Article  PubMed  Google Scholar 

  50. Elliott DS, Blute ML, Patterson DE, et al. Long-term follow-up of endoscopically treated upper urinary tract transitional cell carcinoma. Urology. 1996;47:819.

    Article  CAS  PubMed  Google Scholar 

  51. Keeley FX, Bagley DH. Adjuvant mitomycin C following endoscopic treatment of upper tract transitional cell carcinoma. J Urol. 1997;158:2074.

    Article  CAS  PubMed  Google Scholar 

  52. See WA. Continuous antegrade infusion of adriamycin as adjuvant therapy for upper tract urothelial malignancies. Urology. 2000;56:216.

    Article  CAS  PubMed  Google Scholar 

  53. Burns JA, Williams RD, Hedican SP, O’Donnell MA: The treatment of upper tract transitional cell carcinoma with BCG plus interferon-alpha. In: American urological association annual meeting, 2001.

    Google Scholar 

  54. Katz MH, Lee MW, Gupta M. Setting a new standard for topical therapy of upper-tract transitional-cell carcinoma: BCG and interferon-alpha2B. J Endourol. 2007;21:374.

    Article  PubMed  Google Scholar 

  55. Eshghi M. Upper Tract Urothelial Carcinoma. Presentation of NY-AUA Meeting 2007.

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Urology, Westchester Medical Health Network/New York Medical College, 40 Sunshine Cottage Rd., Valhalla, NY, 10595, USA

    Joel Hillelsohn, Ariel Schulman & Majid Eshghi

  2. Division of Urology, Duke University School of Medicine, Durham, NC, USA

    Ariel Schulman

Authors
  1. Joel Hillelsohn
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Ariel Schulman
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Majid Eshghi
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Joel Hillelsohn .

Editor information

Editors and Affiliations

  1. Chief, Section of Endourology and Minimally Invasive Urology, Westchester Medical Health Network, Valhalla, New York, USA

    Majid Eshghi

Rights and permissions

Reprints and permissions

Copyright information

© 2018 Springer International Publishing AG, part of Springer Nature

About this chapter

Check for updates. Verify currency and authenticity via CrossMark

Cite this chapter

Hillelsohn, J., Schulman, A., Eshghi, M. (2018). Analysis of Conservative Treatment of Upper Tract Urothelial Carcinoma. In: Eshghi, M. (eds) Urothelial Malignancies of the Upper Urinary Tract. Springer, Cham. https://doi.org/10.1007/978-3-319-51263-1_27

Download citation

  • DOI: https://doi.org/10.1007/978-3-319-51263-1_27

  • Published:

  • Publisher Name: Springer, Cham

  • Print ISBN: 978-3-319-51261-7

  • Online ISBN: 978-3-319-51263-1

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation